Future Science Group
Browse
0439 Info.pdf (129.29 kB)

Infographic – Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors

Download (129.29 kB)
Version 2 2022-06-14, 15:24
Version 1 2022-06-14, 09:10
figure
posted on 2022-06-14, 15:24 authored by Taylor & FrancisTaylor & Francis, Mercedes Porosnicu, Anne-Marie Quinson, Kate Crossley, Stephan Luecke, Ulrich M Lauer

Phase I study of VSV-GP (BI 1831169) as  monotherapy or combined with ezabenlimab in advanced and refractory solid tumors 

Funding

Boehringer Ingelheim International GmbH

History

Usage metrics

    Future Oncology

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC